AMY LEWING: Open Payments
NPI 1508481953 · SHREVEPORT, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,553 in 75 payments from 16 companies in 2025. Trend: 2023 $2,176 · 2024 $1,220 · 2025 $1,553
Food & beverage: $1,544Education: $9
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 13 | $289 |
| Ardelyx, Inc. | 12 | $273 |
| ABBVIE INC. | 17 | $241 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $149 |
| Madrigal Pharmaceuticals | 2 | $133 |
| Gilead Sciences, Inc. | 4 | $93 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 4 | $81 |
| GENZYME CORPORATION | 2 | $76 |
| Phathom Pharmaceuticals, Inc. | 5 | $70 |
| Janssen Scientific Affairs, LLC | 1 | $45 |
Products named: TREMFYA, IBSRELA, ENTYVIO, REZDIFFRA, RINVOQ, SKYRIZI, XIFAXAN, DUPIXENT.
Industry payments across LA — which companies pay providers there.
